USPTO granted a pharmaceutical patent covering benzalkonium chloride compositions and methods for treating coronavirus infections and conjunctivitis, including reducing COVID-19 transmission through ophthalmic administration. The patent (US12594251B2) provides intellectual property protection to Bausch + Lomb Ireland Limited for these therapeutic applications.

For pharmaceutical manufacturers and healthcare providers, this patent establishes IP rights that may affect competitive development of benzalkonium chloride-based COVID-19 or conjunctivitis treatments. Generic manufacturers and researchers should review the patent claims for potential licensing needs or freedom-to-operate analysis before developing similar products.